BIOCON
Biocon Limited (BIOCON) Stock Analysis
Biocon Limited is a leading Indian biopharmaceutical company. It develops and manufactures biosimilars, generics, and research services for global and domestic markets. Its businesses span APIs, formulations, and contract research for healthcare customers. The company is listed on Indian stock exchanges and is headquartered in India.
Healthcare › Biotechnology
₹350.60
-2.61% 1W | -2.80% 52W
Market Cap
57.4k CR
P/E Ratio
103.7
52W High
₹447.1
52W Low
₹337.7
Div. Yield
0.14%
Beta
0.3
50 DMA
₹396.3
200 DMA
₹393.1
Profit Margin
2.9%
Inst. Own.
30.8%
✅ BOUNCE FROM SUPPORT
✅ BOUNCE FROM SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,423 | 3,462 | 3,954 | 3,917 | 3,433 | 3,590 | 3,821 | 4,417 | 3,942 | 4,296 | 4,173 | 4,517 | 4,336 |
| Expenses | 2,741 | 2,745 | 3,051 | 3,004 | 2,812 | 2,905 | 3,070 | 3,339 | 3,176 | 3,460 | 3,340 | 3,496 | 3,489 |
| Operating Profit | 681 | 717 | 903 | 913 | 620 | 685 | 752 | 1,078 | 766 | 835 | 834 | 1,020 | 847 |
| OPM % | 20% | 21% | 23% | 23% | 18% | 19% | 20% | 24% | 19% | 19% | 20% | 23% | 20% |
| Other Income | 94 | 134 | 587 | 40 | 1,166 | 58 | 53 | 57 | 62 | 81 | -176 | -28 | 41 |
| Interest | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 | 272 | 210 | 232 | 213 |
| Depreciation | 358 | 389 | 414 | 407 | 405 | 420 | 425 | 436 | 455 | 473 | 515 | 513 | 547 |
| Profit before tax | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 | 97 | 171 | -68 | 248 | 128 |
| Tax % | 19% | 19% | 7% | 30% | 25% | 72% | 48% | 6% | 8% | 22% | -24% | 20% | -7% |
| Net Profit | 149 | 173 | 753 | 223 | 862 | 27 | 81 | 459 | 89 | 133 | -52 | 199 | 137 |
| EPS in Rs | 0.84 | 1.05 | 5.50 | 1.13 | 5.49 | -0.13 | 0.21 | 2.87 | 0.23 | 0.63 | 1.08 | 0.78 | 0.87 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,090 | 3,347 | 3,891 | 4,123 | 5,514 | 6,300 | 7,143 | 8,184 | 11,174 | 14,756 | 15,262 | 16,927 | 17,321 |
| Expenses | 2,394 | 2,957 | 2,912 | 3,294 | 4,121 | 4,696 | 5,562 | 6,391 | 8,762 | 11,540 | 12,008 | 13,456 | 13,785 |
| Operating Profit | 696 | 390 | 980 | 829 | 1,394 | 1,604 | 1,581 | 1,793 | 2,412 | 3,216 | 3,254 | 3,471 | 3,536 |
| OPM % | 23% | 12% | 25% | 20% | 25% | 25% | 22% | 22% | 22% | 22% | 21% | 21% | 20% |
| Other Income | 158 | 639 | 173 | 228 | 340 | 199 | 260 | 72 | 18 | 853 | 1,217 | -76 | -82 |
| Interest | 9 | 29 | 26 | 62 | 71 | 65 | 58 | 68 | 419 | 974 | 897 | 990 | 927 |
| Depreciation | 221 | 249 | 277 | 385 | 448 | 552 | 715 | 814 | 1,113 | 1,569 | 1,687 | 1,957 | 2,049 |
| Profit before tax | 624 | 751 | 850 | 610 | 1,215 | 1,186 | 1,068 | 983 | 897 | 1,525 | 1,887 | 448 | 479 |
| Tax % | 15% | 19% | 19% | 26% | 17% | 27% | 21% | 22% | 28% | 15% | 24% | 18% | |
| Net Profit | 528 | 609 | 688 | 453 | 1,003 | 871 | 846 | 772 | 643 | 1,298 | 1,429 | 369 | 416 |
| EPS in Rs | 4.14 | 4.59 | 5.10 | 3.10 | 7.54 | 6.24 | 6.17 | 5.40 | 3.85 | 8.52 | 8.44 | 2.38 | 3.36 |
| Dividend Payout % | 20% | 18% | 10% | 16% | 7% | 0% | 0% | 9% | 39% | 6% | 6% | 21% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 15.0% | 19.0% | 18.0% |
| Profit CAGR | -15.0% | -12.0% | 1.0% |
Shareholding Pattern
Promoters54.45%
FIIs6.04%
DIIs22.83%
Public16.51%
Promoters54.45%
FIIs6.61%
DIIs22.06%
Public16.70%
Promoters54.45%
FIIs7.39%
DIIs21.67%
Public16.34%
Promoters44.91%
FIIs7.52%
DIIs24.01%
Public23.40%
Promoters44.68%
FIIs8.14%
DIIs23.33%
Public23.75%
Promoters60.64%
FIIs10.20%
DIIs11.89%
Public16.70%
Promoters60.64%
FIIs5.63%
DIIs13.69%
Public19.74%
Promoters60.64%
FIIs5.67%
DIIs15.73%
Public17.77%
Promoters44.91%
FIIs7.52%
DIIs24.01%
Public23.40%
Promoters44.68%
FIIs8.14%
DIIs23.33%
Public23.75%
BIOCON
Holdings Analysis
Key strengths & risk signals
62
Overall
57
Fundamental
68
Technical
Risks (4)
Cannot calculate PEG - insufficient growth data.
WEAK POSITION! Current price (351.0) is below both moving averages.
WEAK! Trading at 12.2% of 52W range - near yearly lows.
NEGATIVE MOMENTUM! Price declined across timeframes - down 4.9% (1 week), 10.2% (1 month), 19.2% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (397.9) is above 200-day average (393.3) - positive signal.
OVERSOLD! RSI at 28.0 - potential bounce opportunity.
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
Fundamental & Technical Analysis
62Overall
57Fundamental
68Technical
Fundamental Breakdown
Growth Quality
15/30
Revenue CAGR: 15.3% (VERY GOOD, 13/15). Profit CAGR: -5.9% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! 2.9% profit margin - thin profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.14% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
16/20
LESS PUBLIC HOLDING! 16.77% public ownership - good institutional/promoter control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
10/10
BULLISH TREND! 50-day average (396.3) is above 200-day average (393.1) - positive signal.
Price Position
2/10
WEAK POSITION! Current price (350.6) is below both moving averages.
Trend Pattern
16/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
3/10
WEAK YEAR! Stock declined 2.8% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 10 up days, 20 down days. Avg volume on up days: 3,865,059 vs down days: 2,718,966. Ratio: 1.42x
RSI
5/5
OVERSOLD! RSI at 27.8 - potential bounce opportunity.
52W Range
1/5
WEAK! Trading at 11.8% of 52W range - near yearly lows.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 2.6% (1 week), 10.2% (1 month), 20.4% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
BIOCON
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-11 | Concall PDF | |
| Q4FY262026-05-14 | Concall PDF | |
| Q3FY262026-02-17 | Concall PDF | |
| Q2FY262025-11-18 | Concall PDF |
Peer Comparison
Healthcare · Biotechnology · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIOCON | ₹350.60 | 103.7 | 2.9% | 15.3% | -5.9% | -2.8% | 62 | BOUNCE FROM SUPPORT | +349.4% | +12.1% | +9.8% | -4.3% |
| ANTHEM | ₹847.80 | 83.5 | 28.7% | 26.2% | 15.4% | +12.2% | 74 | BREAKDOWN | -11.7% | -36.8% | -22.6% | -31.5% |
| ONESOURCE | ₹1,442.40 | – | -3.1% | 232.4% | – | -20.4% | 44 | BREAKDOWN | -12,600.0% | +443.5% | +37.2% | +4.9% |
| CONCORDBIO | ₹1,382.10 | 48.1 | 24.8% | 8.0% | 2.8% | -10.2% | 56 | BREAKDOWN | +30.8% | -35.0% | +26.2% | -21.0% |
| BLUEJET | ₹522.50 | 38.6 | 26.5% | 9.4% | 15.7% | -21.6% | 69 | BREAKDOWN | -14.1% | +21.8% | -17.4% | +24.9% |
| SUPRIYA | ₹874.50 | 35.5 | 22.7% | 21.2% | 32.5% | +22.4% | 81 | BREAKDOWN | -31.0% | -67.7% | +30.7% | -31.4% |
| ZOTA | ₹1,420.10 | – | -17.0% | 56.7% | – | -13.6% | 54 | APPROACHING RESISTANCE | +204.9% | +207.0% | +67.6% | +6.4% |
| DCAL | ₹153.00 | 148.6 | 0.6% | 9.0% | 21.0% | -48.1% | 50 | APPROACHING RESISTANCE | -347.9% | -367.3% | -4.2% | -20.4% |
Data from TradeAlone · Updated daily
BIOCON News
Biocon Limited (biocon) Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval2026-09-21Biocon Limited (biocon) Secures 10-year Supply Contract for Pertuzumab in Brazil2026-09-08Biocon Limited (biocon) Q1 FY27: Revenue Up 9%, Biosimilars Lead Growth2026-08-06Biocon Limited Q1 FY27: Total Income at Rs 4,391 Cr, Up 9%2026-08-05Biocon Limited (biocon) Announces U.S. Launch of Yesafili™ Biosimilar2026-08-03Biocon Limited (NSE: BIOCON) gains 5% intraday, tests resistance2026-07-14Biocon Limited (biocon) Publishes Pivotal Clinical Data for Yesafili™2026-07-09Biocon Limited (biocon) Reinforces Commitment to Diabetes Care in Malaysia2026-06-24Biocon Limited Reports Strong Q4 and Full Year Fy26 Results2026-05-08
